Medical Insight+

PurpleAI, operating under the name Medical Insight+, is a specialized medical artificial intelligence company that originated as a spin-off from the South Korean conglomerate SK Inc. The company is sharply focused on transforming cerebrovascular disease care, particularly in the acute stroke sector.

The firm's core offering is Hyper Insight - ICH™, a cloud-based clinical decision support tool. This software as a medical device (SaMD) received FDA 510(k) clearance on July 1, 2024, after a submission on February 5, 2024. Hyper Insight - ICH™ is engineered to analyze non-contrast CT (NCCT) brain scans with the aid of deep learning algorithms. Its primary function is to detect suspected intracranial hemorrhages and promptly notify medical specialists, thereby facilitating faster and more accurate triage in emergency situations. A retrospective study demonstrated the software's high performance, with a sensitivity of 95.45% and a specificity of 98.47%.

PurpleAI's business model targets healthcare providers, specifically community hospitals and telestroke services. The solution is designed for seamless integration into existing clinical workflows, functioning as a notification aid that runs in parallel with standard patient care protocols to enhance efficiency. It analyzes images and provides a binary output indicating the suspected presence of acute ICH for notification purposes, rather than serving as a direct diagnostic tool. By delivering critical information within seconds, the system aims to bring greater speed, precision, and scalability to stroke care, where timely intervention is paramount.

Keywords: Medical Insight+, PurpleAI, SK Inc. spin-off, medical AI, stroke care, cerebrovascular disease, Hyper Insight - ICH, FDA clearance, clinical decision support, intracranial hemorrhage, brain hemorrhage detection, non-contrast CT, telestroke, emergency medicine, deep learning, SaMD, medical imaging, healthcare technology, neurovascular AI, radiology AI